Objectives:

To evaluate the effectiveness and safety of panitumumab in patients with metastatic colorectal cancer and to compare the results obtained with those published in clinical trials.

Material and methods:

Retrospective observational study of patients with metastatic colorectal cancer treated with panitumumab from June 2010 to September 2017. Demographic, clinical and therapeutic data were collected from the computerised clinical history. The main effectiveness endpoints were: progression-free survival, overall survival and type of response to treatment. Adverse events and their severity established the safety profile.

Results:

85 patients, 60 males, were included. The overall response rate was 17.8%, of which 15.3% were partial responses. Disease stabilisation occu rred in 14% and disease progression in 51.8%. Median progression-free survival was 6 months (95% CI 4.7-6.2). Treatment was generally well tolerated.The most frequent toxicity wasskin toxicity, affecting 82.4% of patients.

Conclusions:

Panitumumab is a therapy with acceptable effectiveness and tolerability in treatment of mRCC in KRAS WT population. The combination of the drug with chemotherapy regimens produces a significant improvement in progression-free survival.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )